Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

Seminars in Oncology

Volumn 42, Issue 4, 2015, Pages 539-548

  Floros, Theofanis ^a,b   Tarhini, Ahmad A ^a,c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; BIOLOGICAL MARKER; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; ALPHA INTERFERON; CYTOKINE; INTERLEUKIN DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; CYTOKINES; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; INTERLEUKINS; NEOPLASMS;

EID: 84940395868     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.05.015     Document Type: Review

References (105)

1. J.M. Kirkwood, and M. Ernstoff Melanoma: rapeutic options with recombinant interferons Semin Oncol 12 4 Suppl 5 1985 7 12
2. G. Fyfe, R.I. Fisher, S.A. Rosenberg, M. Sznol, D.R. Parkinson, and A.C. Louie Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 rapy J Clin Oncol 13 3 1995 688 696
3. M.B. Atkins, M.T. Lotze, J.P. Dutcher, and et al. High-dose recombinant interleukin 2 rapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 7 1999 2105 2116
4. F.P. Siegal, N. Kadowaki, M. Shodell, and et al. nature of principal type 1 interferon-producing cells in human blood Science (New York, NY) 284 5421 1999 1835 1837
5. C.B. Thompson, and J.P. Allison emerging role of CTLA-4 as an immune attenuator Immunity 7 4 1997 445 450
6. S. Parlato, S.M. Santini, C. Lapenta, and et al. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for rapid acquisition of potent migratory and functional activities Blood 98 10 2001 3022 3029
7. T. Zhang, H.C. Sun, H.Y. Zhou, and et al. Interferon alpha inhibits hepatocellular carcinoma growth through inducing apoptosis and interfering with adhesion of tumor endolial cells Cancer Lett 290 2 2010 204 210
8. E.T. Creagan, D.L. Ahmann, S. Frytak, H.J. Long, M.N. Chang, and L.M. Itri Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients Cancer Treat Rep 70 5 1986 619 624
9. O. Eton, S.S. Legha, A.Y. Bedikian, and et al. Sequential biochemorapy versus chemorapy for metastatic melanoma: results from a phase III randomized trial J Clin Oncol 20 8 2002 2045 2052
10. A.A. Tarhini, J. Cherian, S.J. Moschos, and et al. Safety and efficacy of combination immunorapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma J Clin Oncol 30 3 2012 322 328
11. M.B. Atkins, J. Hsu, S. Lee, and et al. Phase III trial comparing concurrent biochemorapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): A trial coordinated by Eastern Cooperative Oncology Group J Clin Oncol 26 35 2008 5748 5754
12. E.T. Creagan, R.J. Dalton, D.L. Ahmann, and et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma J Clin Oncol 13 11 1995 2776 2783
13. J.M. Kirkwood, M.H. Strawderman, M.S. Ernstoff, T.J. Smith, E.C. Borden, and R.H. Blum Interferon alfa-2b adjuvant rapy of high-risk resected cutaneous melanoma: Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 1 1996 7 17
14. A.A. Tarhini, and J.M. Kirkwood How much of a good thing? What duration for interferon alfa-2b adjuvant rapy? J Clin Oncol 30 31 2012 3773 3776
15. A.M. Eggermont, S. Suciu, A. Testori, and et al. Long-term results of randomized phase III trial EORTC 18991 of adjuvant rapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma J Clin Oncol 30 31 2012 3810 3818
16. S.J. Moschos, H.D. Edington, S.R. Land, and et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses J Clin Oncol 24 19 2006 3164 3171
17. A.A. Tarhini, and P.M. Thalanayar Melanoma adjuvant rapy Hematol Oncol Clin North Am 28 3 2014 471 489
18. A.J. Scherr, J.P. Lima, E.C. Sasse, C.S. Lima, and A.D. Sasse Adjuvant rapy for locally advanced renal cell cancer: A systematic review with meta-analysis BMC Cancer 11 2011 115
19. M. Aitchison, C.A. Bray, H. Van Poppel, and et al. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial Eur J Cancer 50 1 2014 70 77
20. R.J. Motzer, B.A. Murphy, J. Bacik, and et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma J Clin Oncol 18 16 2000 2972 2980
21. B. Escudier, J. Bellmunt, S. Negrier, and et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival J Clin Oncol 28 13 2010 2144 2150
22. B.I. Rini, S. Halabi, J.E. Rosenberg, and et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monorapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206 J Clin Oncol 28 13 2010 2137 2143
23. H. Gogas, J. Ioannovich, U. Dafni, and et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon N Engl J Med 354 7 2006 709 718
24. M.G. Bouwhuis, S. Suciu, S. Collette, and et al. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon J Natl Cancer Inst 101 12 2009 869 877
25. A.A. Tarhini, D. Shin, S.J. Lee, J. Stuckert, C.A. Sander, and J.M. Kirkwood Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa Melanoma Res 24 2 2014 150 157
26. A.A. Tarhini, J. Stuckert, S. Lee, C. Sander, and J.M. Kirkwood Prognostic significance of serum S100B protein in high-risk surgically resected melanoma patients participating in Intergroup Trial ECOG 1694 J Clin Oncol 27 1 2009 38 44
27. A.M. Eggermont, S. Suciu, A. Testori, and et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of phase III adjuvant trials EORTC 18952 and EORTC 18991 Eur J Cancer 48 2 2012 218 225
28. A.A. Tarhini, L.H. Butterfield, Y. Shuai, W.E. Gooding, P. Kalinski, and J.M. Kirkwood Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-alpha or TLR-9 agonist and GM-CSF with peptide vaccination J Immunor 35 9 2012 702 710
29. F. Granucci, C. Vizzardelli, N. Pavelka, and et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis Nat Immunol 2 9 2001 882 888
30. S.L. Gaffen, and K.D. Liu Overview of interleukin-2 function, production and clinical applications Cytokine 28 3 2004 109 123
31. + regulatory T cells in cancer patients Blood 107 6 2006 2409 2414
32. Y. Refaeli, L. Van Parijs, C.A. London, J. Tschopp, and A.K. Abbas Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis Immunity 8 5 1998 615 623
33. D.C. Gallagher, R.S. Bhatt, S.M. Parikh, and et al. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak Clin Cancer Res 13 7 2007 2115 2120
34. W.E. Samlowski, M. Kondapaneni, S. Tharkar, J.R. McGregor, V.E. Laubach, and D. Salvemini Endolial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome J Immunor 34 5 2011 419 427
35. D.J. Schwartzentruber High-dose interleukin-2 is an intensive treatment regardless of venue of administration Cancer J 7 2 2001 103 104
36. S.A. Rosenberg, M.T. Lotze, J.C. Yang, and et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for treatment of patients with advanced cancer J Natl Cancer Inst 85 8 1993 622 632
37. +) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma J Clin Oncol 17 8 1999 2521 2529
38. M.J. Besser, R. Shapira-Frommer, A.J. Treves, and et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients Clin Cancer Res 16 9 2010 2646 2655
39. M.E. Dudley, J.C. Yang, R. Sherry, and et al. Adoptive cell rapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens J Clin Oncol 26 32 2008 5233 5239
40. G.Q. Phan, P. Attia, S.M. Steinberg, D.E. White, and S.A. Rosenberg Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma J Clin Oncol 19 15 2001 3477 3482
41. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma J Clin Oncol 24 7 2006 1169 1177
42. M. Atkins, M. Regan, D. McDermott, and et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 rapy for renal cancer Clin Cancer Res 11 10 2005 3714 3721
43. M. Sabatino, S. Kim-Schulze, M.C. Panelli, and et al. Serum vascular endolial growth factor and fibronectin predict clinical response to high-dose interleukin-2 rapy J Clin Oncol 27 16 2009 2645 2652
44. R.J. Sullivan, Y. Hoshida, J. Brunet, and et al. A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response [abstract] J Clin Oncol 27 2009 15s (suppl; abstract 9003)
45. R.W. Joseph, R.J. Sullivan, R. Harrell, and et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma J Immunor 35 1 2012 66 72
46. U. Keilholz, C.J. Punt, M. Gore, and et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of European Organisation for Research and Treatment of Cancer Melanoma Group J Clin Oncol 23 27 2005 6747 6755
47. D.J. Schwartzentruber, D.H. Lawson, J.M. Richards, and et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma N Engl J Med 364 22 2011 2119 2127
48. A.V. Maker, G.Q. Phan, P. Attia, and et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study Ann Surg Oncol 12 12 2005 1005 1016
49. G. Procopio, E. Verzoni, S. Bracarda, and et al. Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): Final results of ROSORC trial Ann Oncol 24 12 2013 2967 2971
50. U.B. Dandamudi, M. Ghebremichael, J.A. Sosman, and et al. A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: A Cytokine Working Group (CWG) study J Immunor 36 9 2013 490 495
51. S.K. Seung, B.D. Curti, M. Crittenden, and et al. Phase 1 study of stereotactic body radiorapy and interleukin-2 - tumor and immunological responses Science translational medicine 4 137 2012 137ra74
52. A. Ma, R. Koka, and P. Burkett Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis Ann Rev Immunol 24 2006 657 679
53. A. Mishra, L. Sullivan, and M.A. Caligiuri Molecular pathways: interleukin-15 signaling in health and in cancer Clin Cancer Res 20 8 2014 2044 2050
54. J.G. Giri, D.M. Anderson, S. Kumaki, L.S. Park, K.H. Grabstein, and D. Cosman IL-15a novel T cell growth factor that shares activities and receptor components with IL-2 J Leukoc Biol 57 5 1995 763 766
55. F. Mattei, G. Schiavoni, F. Belardelli, and D.F. Tough IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation J Immunol 167 3 2001 1179 1187
56. + T cell subsets Immunity 31 5 2009 811 822
57. J.P. Lodolce, D.L. Boone, S. Chai, and et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation Immunity 9 5 1998 669 676
58. W. Wang, M. Meng, Y. Zhang, and et al. Global transcriptome-wide analysis of CIK cells identify distinct roles of IL-2 and IL-15 in acquisition of cytotoxic capacity against tumor BMC Med Genom 7 2014 49
59. F. Tamzalit, I. Barbieux, A. Plet, and et al. IL-15.IL-15Ralpha complex shedding following trans-presentation is essential for survival of IL-15 responding NK and T cells Proc Natl Acad Sci U S A 111 23 2014 8565 8570
60. N.D. Huntington, H. Puthalakath, P. Gunn, and et al. Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1 Nat Immunol 8 8 2007 856 863
61. E. Huarte, J. Fisher, M.J. Turk, and et al. Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunorapy in melanoma Cancer Lett 285 1 2009 80 88
62. T.A. Stoklasek, K.S. Schluns, and L. Lefrancois Combined IL-15/IL-15Ralpha immunorapy maximizes IL-15 activity in vivo J Immunol 177 9 2006 6072 6080
63. W. Xu, M. Jones, B. Liu, and et al. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma Cancer Res 73 10 2013 3075 3086
64. K.C. Conlon, E. Lugli, H.C. Welles, and et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer J Clin Oncol 33 1 2015 74 82
65. A. Vogelzang, H.M. McGuire, D. Yu, J. Sprent, C.R. Mackay, and C. King A fundamental role for interleukin-21 in generation of T follicular helper cells Immunity 29 1 2008 127 137
66. T. Habib, S. Senadheera, K. Weinberg, and K. Kaushansky common gamma chain (gamma c) is a required signaling component of IL-21 receptor and supports IL-21-induced cell proliferation via JAK3 Biochemistry 41 27 2002 8725 8731
67. R. Zeng, R. Spolski, E. Casas, W. Zhu, D.E. Levy, and W.J. Leonard molecular basis of IL-21-mediated proliferation Blood 109 10 2007 4135 4142
68. Y.W. Zhang, L.M. Wang, R. Jove, and G.F. Vande Woude Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis Oncogene 21 2 2002 217 226
69. G. Monteleone, R. Caruso, D. Fina, and et al. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21 Gut 55 12 2006 1774 1780
70. K. Ozaki, R. Spolski, C.G. Feng, and et al. A critical role for IL-21 in regulating immunoglobulin production Science (New York, NY) 298 5598 2002 1630 1634
71. + T cells for adoptive immunorapy Blood 111 11 2008 5326 5333
72. M.T. Kasaian, M.J. Whitters, L.L. Carter, and et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: A mediator of transition from innate to adaptive immunity Immunity 16 4 2002 559 569
73. B. Rodriguez-Bayona, A. Ramos-Amaya, J. Bernal, A. Campos-Caro, and J.A. Brieva Cutting edge: IL-21 derived from human follicular helper T cells acts as a survival factor for secondary lymphoid organ, but not for bone marrow, plasma cells J Immunol 188 4 2012 1578 1581
74. H. Jin, R. Carrio, A. Yu, and T.R. Malek Distinct activation signals determine wher IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis J Immunol 173 1 2004 657 665
75. H.L. Ma, M.J. Whitters, R.F. Konz, and et al. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma J Immunol 171 2 2003 608 615
76. H. He, P. Wisner, G. Yang, and et al. Combined IL-21 and low-dose IL-2 rapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model J Translat Med 4 2006 24
77. Petrella TM, et al. editors. A randomized phase II study of rIL-21 vs dacarbazine in patients with metastatic or recurrent melanoma. ASCO Annual Meeting; 2013; Chicago, IL.
78. T.M. Petrella, R. Tozer, K. Belanger, and et al. Interleukin-21 has activity in patients with metastatic melanoma: A phase II study J Clin Oncol 30 27 2012 3396 3401
79. S. Bhatia, B. Curti, M.S. Ernstoff, and et al. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: A phase 1/2 study J Immunor Cancer 2 2014 2
80. V. Grunwald, I.M. Desar, J. Haanen, and et al. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC) Acta Oncol 50 1 2011 121 126
81. J.M. Timmerman, J.C. Byrd, D.J. Andorsky, and et al. A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders Clin Cancer Res 18 20 2012 5752 5760
82. M.J. Smyth, M. Taniguchi, and S.E. Street anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent J Immunol 165 5 2000 2665 2670
83. U. Sahin, S. Kraft-Bauer, S. Ohnesorge, M. Pfreundschuh, and C. Renner Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors Cancer Immunol Immunor 42 1 1996 9 14
84. G. Trinchieri Interleukin-12 and regulation of innate resistance and adaptive immunity Nat Rev Immunol 3 2 2003 133 146
85. W.E. Thierfelder, J.M. van Deursen, K. Yamamoto, and et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells Nature 382 6587 1996 171 174
86. L. Rogge, L. Barberis-Maino, M. Biffi, and et al. Selective expression of an interleukin-12 receptor component by human T helper 1 cells J Exp Med 185 5 1997 825 831
87. T. Kobayashi, K. Shiiba, M. Satoh, and et al. Interleukin-12 administration is more effective for preventing metastasis than for inhibiting primary established tumors in a murine model of spontaneous hepatic metastasis Surgery Today 32 3 2002 236 242
88. + T effectors J Immunol 177 10 2006 6962 6973
89. J. Zhao, J. Zhao, and S. Perlman Differential effects of IL-12 on Tregs and non-Treg T cells: roles of IFN-gamma IL-2 and IL-2R. PloS One 7 9 2012 e46241
90. V. Pistoia, C. Cocco, and I. Airoldi Interleukin-12 receptor beta2: From cytokine receptor to gatekeeper gene in human B-cell malignancies J Clin Oncol 27 28 2009 4809 4816
91. I. Airoldi, E. Di Carlo, C. Cocco, and et al. Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy Blood 106 12 2005 3846 3853
92. W. Su, T. Ito, T. Oyama, T. Kitagawa, T. Yamori, H. Fujiwara, and et al. direct effect of IL-12 on tumor cells: IL-12 acts directly on tumor cells to activate NF-kappaB and enhance IFN-gamma-mediated STAT1 phosphorylation Biochem Biophys Res Commun 280 2 2001 503 512
93. J.P. Leonard, M.L. Sherman, G.L. Fisher, and et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production Blood 90 7 1997 2541 2548
94. M.B. Atkins, M.J. Robertson, M. Gordon, and et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies Clin Cancer Res 3 3 1997 409 417
95. M. Duvic, M.L. Sherman, G.S. Wood, and et al. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides J Am Acad Dermatol 55 5 2006 807 813
96. P. Lee, F. Wang, J. Kuniyoshi, and et al. Effects of interleukin-12 on immune response to a multipeptide vaccine for resected metastatic melanoma J Clin Oncol 19 18 2001 3836 3847
97. O. Hamid, J.C. Solomon, R. Scotland, and et al. Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: Correlation with time to relapse in patients with resected high-risk disease Clin Cancer Res 13 1 2007 215 222
98. F. Cavallo, P. Signorelli, M. Giovarelli, and et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or or cytokines compared with exogenous IL-12 J Natl Cancer Inst 89 14 1997 1049 1058
99. C.M. van Herpen, R. van der Voort, J.A. van der Laak, and et al. Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation Int J Cancer 123 10 2008 2354 2361
100. D.M. Mahvi, M.B. Henry, M.R. Albertini, and et al. Intratumoral injection of IL-12 plasmid DNA - results of a phase I/IB clinical trial Cancer Gene r 14 8 2007 717 723
101. P.L. Triozzi, K.O. Allen, R.R. Carlisle, M. Craig, A.F. LoBuglio, and R.M. Conry Phase I study of intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma Clin Cancer Res 11 11 2005 4168 4175
102. A.I. Daud, R.C. DeConti, S. Andrews, and et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma J Clin Oncol 26 36 2008 5896 5903
103. K. Anwer, F.J. Kelly, C. Chu, J.G. Fewell, D. Lewis, and R.D. Alvarez Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemorapy in treatment of platinum-sensitive recurrent ovarian cancer Gynecol Oncol 131 1 2013 169 173
104. R.D. Alvarez, M.W. Sill, S.A. Davidson, and et al. A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in treatment of persistent or recurrent epilial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study Gynecol Oncol 133 3 2014 433 438
105. J. Fallon, R. Tighe, G. Kradjian, and et al. immunocytokine NHS-IL12 as a potential cancer rapeutic Oncotarget 5 7 2014 1869 1884